The views expressed in this article are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health.
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals
Version of Record online: 26 AUG 2013
© 2013 The Authors. Hepatology published by Wiley on behalf of the American Association for the Study of Liver Diseases
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Volume 58, Issue 5, pages 1598–1609, November 2013
How to Cite
Martin, N. K., Vickerman, P., Grebely, J., Hellard, M., Hutchinson, S. J., Lima, V. D., Foster, G. R., Dillon, J. F., Goldberg, D. J., Dore, G. J. and Hickman, M. (2013), Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology, 58: 1598–1609. doi: 10.1002/hep.26431
This work was produced under the terms of the postdoctoral research training fellowship (to N. K. M.) issued by the National Institute for Health Research (NIHR). P. V. was supported by Medical Research Council New Investigator Award G0801627. J. G. was supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship. M. Hellard was supported by an NHMRC Project Grant and the Victorian Operational Infrastructure Support Program. V. D. L. was supported by a National Institute on Drug Abuse Michael Smith Foundation for Health Research Scholar Award. G. J. D. was supported by a NHMRC Practitioner Research Fellowship. The Kirby Institute is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, University of New South Wales. M. Hickman was supported by the NIHR School of Public Health Nationally Integrated Quantitative Understanding of Addiction Harm MRC addiction research cluster and The Centre for the Development and Evaluation of Complex Interventions for Public Health Improvement, a UK Clinical Research Collaboration (UKCRC) Public Health Research Centre of Excellence. Funding was also received from the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council (grant RES-590-28-0005), the Medical Research Council, the Welsh Assembly Government, and the Wellcome Trust (grant WT087640MA) under the auspices of the UKCRC.
Potential conflict of interest: N. K. M. has received an honorarium for speaking at a conference sponsored by Janssen. J. G. owns stock in Gilead and is a member of an advisory board for Merck. S. J. H. has received honoraria for speaking at conferences sponsored by MSD and Janssen and consults for Janssen. G. R. F. has received funding from Roche, Novartis, Janssen, Gilead, Bristol-Meyers Squibb, Boehringer Ingelheim, Idenix, Abbott, and Merck for consultancy and lectures. D. J. G. is a member of advisory boards and undertakes consultancy for Merck and Janssen. G. J. D. is a consultant/advisor and has received research grants from Roche, Merck, Janssen, Gilead, Bristol-Myers Squibb, and Abbott.
See Editorial on Page 1523
- Issue online: 30 OCT 2013
- Version of Record online: 26 AUG 2013
- Accepted manuscript online: 28 MAR 2013 08:03AM EST
- Manuscript Accepted: 24 MAR 2013
- Manuscript Received: 10 JAN 2013
- 7Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007;102:1454–1462., , , , .
- 19Australian Needle and Syringe Program National Data Report 2007-2011. Kensington, Australia: The Kirby Institute; 2012., .
- 26Health Protection Scotland and the University of the West of Scotland. The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV, HIV and Injecting Risk Behaviours Among Injecting Drug Users Attending Needle Exchanges in Scotland, 2007. Glasgow, UK: Health Protection Scotland; 2008.
- 27Australian NSP Survey National Data Report 1995-2010. Kensington, Australia: The Kirby Institute; 2011., , .
- 30Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health 2009:1–9., , , , , , et al.
- 33Urban Health Research Initiative of the British Columbia Centre for Excellence in HIV/AIDS. Drug situation in Vancouver. Vancouver, Canada: 2009. http://uhri.cfenet.ubc.ca/images/Documents/dsiv2009.pdf. Accessed April 2013.
- 36University of the West of Scotland, Health Protection Scotland, and West of Scotland Specialist Virology Centre. The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV and Injecting Risk Behaviours Among Injecting Drug Users Attending Needle Exchanges in Scotland, 2008/2009; 2010. http://www.documents.hps.scot.nhs.uk/bbvsti/hepatitis-c/publications/nesi-needle-exchange.pdf. Accessed April 2013.
- 37Treatment of HCV infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. In press., , , , , , et al.
- 41WHO/UNAIDS/UNICEF. Global HIV/AIDS Response: Epidemic Update And Health Sector Progess Towards Universal Access; 2011.
- 43Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009;338., , , , , , et al.
- 51Estimating the National and Local Prevalence of Problem Drug Misuse in Scotland. University of Glasgow Centre for Drug Misuse Research and Health Protection Scotland. http://www.drugmisuse.isdscotland.org/publications/local/prevreport2004.pdf. Accessed on April 2013., , , , .
- 52Victorian Drug Trends 2011: Findings from the Illicit Drug Reporting System (IDRS). Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales; 2012., , .
- 63National Institute for Health and Clinical Excellence. Peginterferon alfa and Ribavirin for the Treatment of Mild Chronic Hepatitis C. NICE Technology Appraisal Guidance 106; 2006.